Cresco Labs Inc (CRLBF)

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the third quarter ended September 30, 2026. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company’s investor website, here.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (“Cresco Labs” or the “Company”), today announced two new additions to its portfolio of leading cannabis brands: High Supply SLIPS—fast-acting oral THC pouches—and Wonder THC Drink Mixes—single-serving beverage packets. The launches reflect the Company's focus on identifying unmet consumer needs, creating new consumer occasions, and developing products that bring new audiences into the regulated cannabis market.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the results of its annual general and special meeting of shareholders (the “Meeting”) held on October 30, 2026.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the grand opening of Sunnyside Prestonsburg in Kentucky, the Company’s 83rd dispensary nationwide.

Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Friday, November 6, 2026.

Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company") today announced that it has filed a supplement (the "Supplement") to its management information circular dated September 18, 2026 (the "Circular") in connection with its annual general and special meeting of shareholders to be held on October 30, 2026. The Supplement enhances and clarifies the disclosure in the Circular concerning the proposed amendment to Cresco's super-voting shares and related minority approval requirements.

Innovative Industrial Properties and Trulieve Cannabis may be turning things around.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company") today announced that it has filed its Management Information Circular (the "Circular") and related proxy materials for its annual general and special meeting of shareholders to be held on October 30, 2026 (the “Meeting”), as it prepares for a potential listing on a senior U.S. exchange.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced the appointment of Edward Tilly to its Board of Directors, effective September 18, 2026. Mr. Tilly will serve as an independent director and join the Audit Committee, bringing the Board to eight directors.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC (“PharmaCann”) for an aggregate consideration of US$50 million (the “Transaction”). The Transaction consists of nine operational retail medical marijuana dispensaries in Pennsylvania, advancing Cresco’s leadership position in the second-largest medical marijuana market, which generated more than US$1.1 billion1 in annual sales last year.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the second quarter ended June 30, 2026. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company’s investor website, here.

Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced it will report financial results for the quarter ended June 30th, 2026 on Thursday, August 6, 2026 before the market opens.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of a credit agreement with Needham Bank, a Massachusetts-based commercial bank, providing the Company with a US$50 million revolving credit facility (the “Facility”).

It isn't easy to find a marijuana company that can turn a profit.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced that it registered certain state-licensed medical cannabis facilities with the U.S. Drug Enforcement Administration (“DEA”) following the federal rescheduling of medical cannabis to Schedule III under the Controlled Substances Act. The registrations are related to dispensary, cultivation and processing operations serving medical cannabis patients in the Company’s footprint.

Cannabis company Green Thumb is younger and in a different sector than consumer staples giant Procter & Gamble, but it's succeeding with similar methods.

Georgia Governor Brian Kemp has approved legislation that broadens access to the state’s medical cannabis program, introducing several changes aimed at expanding treatment options for eligible patients while maintaining restrictions on recreational marijuana. The measure, Senate Bill 220, adds new qualifying medical conditions, revised rules on THC limits, and expanded methods for how patients may use cannabis products.

Georgia Governor Brian Kemp has approved legislation that broadens access to the state’s medical cannabis program, introducing several changes aimed at expanding treatment options for eligible patients while maintaining restrictions on recreational marijuana. The measure, Senate Bill 220, adds new qualifying medical conditions, revised rules on THC limits, and expanded methods for how patients may use cannabis products.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today provided an update on its application under the Texas Compassionate Use Program (TCUP). The Texas Department of Public Safety (DPS) has announced a retroactive correction to the tabulation methodology used in its conditional license selection process, impacting multiple applicants. Under the corrected tabulation, the conditional license previously awarded and publicly announced by DPS for Cresco Labs Texas, LLC has been rescinded, and Cresco Labs Texas, LLC has been placed on the TCUP eligibility list. Cresco Labs maintains that its application merits a conditional license, as originally determined by DPS, and is evaluating its options to work with the state to protect that determination.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the first quarter ended March 31, 2026. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company’s investor website, here.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the grand opening of Sunnyside Aberdeen, located in Aberdeen, Ohio. This marks the Company's second Ohio dispensary opening in the past month, increasing its footprint to eight locations statewide and 74 nationally.

April 20, widely known as 4/20, has become an informal holiday associated with cannabis use. As public attitudes continue to shift and legalization spreads across the U.S., more public officials and companies are openly acknowledging the day. This year, messages shared online reflected a mix of celebration, policy advocacy, and public safety reminders.

April 20, widely known as 4/20, has become an informal holiday associated with cannabis use. As public attitudes continue to shift and legalization spreads across the U.S., more public officials and companies are openly acknowledging the day. This year, messages shared online reflected a mix of celebration, policy advocacy, and public safety reminders.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell in response to the Department of Justice’s final rule publication rescheduling medical cannabis from Schedule I to Schedule III under the Controlled Substances Act.